Using cardiac magnetic resonance imaging to detect early changes in heart muscle that may help predict patients who are at risk of developing toxicity from anthracycline chemotherapy.

This study is testing whether a special type of heart MRI (called T2 mapping) can detect early damage to the heart muscle caused by anthracycline chemotherapy — a type of cancer treatment used for conditions like lymphoma. Anthracyclines can sometimes harm the heart, but this damage often isn't detected until the heart has already weakened significantly. Researchers hope that T2 mapping can spot early warning signs by detecting swelling in the heart muscle, allowing doctors to step in earlier to protect patients. You may be eligible if: - You are between 18 and 90 years old - You have been referred for anthracycline chemotherapy (for example, for lymphoma) - OR you are a healthy volunteer acting as a comparison participant You may NOT be eligible if: - Your kidneys are not working well enough (GFR below 60 mL/kg/1.73m²) - You have a reason you cannot have an MRI scan - You are allergic to gadolinium (MRI contrast dye) - You have atrial fibrillation at the start of the study - You are pregnant Talk to your doctor about whether this trial might be right for you.